May Guo About mRNA Based in Vivo MG1113 Antibody Production as a Potential Therapeutic Approach for Hemophilia
May Guo, Vice President of Business Development at Biomay AG and Founder and CEO of Novaribo Consulting, shared a post on her LinkedIn account:
“mRNA/LNP encoding MG1113, a humanized monoclonal antibody that targets tissue factor pathway inhibitor (TFPI), to treat hemophilia. This paper shows that a single IV dose of mRNA-LNP achieves substantially higher peak serum concentrations of MG1113 antibody compared with direct antibody administration, demonstrating the pharmacokinetic advantage of mRNA-encoded antibody delivery.”
Title: mRNA based in vivo MG1113 antibody production as a potential therapeutic approach for hemophilia
Authors: Miyoung Oh, Yujeong Jeong, Hyein Jung, Yongjoo Byeon, Heechun Kwak, Songseop Kim, Wonhyo Seo, Jaesung Jung, Hyukjin Lee
Find more posts on Hemostasis Today.
-
Jun 29, 2026, 20:09Mamta Soni: The Role of Anti-Xa Monitoring in Anticoagulation Management
-
Jun 29, 2026, 20:07Nita Radhakrishnan: Discussing Risks, Benefits, and Uncertainties in Hemoglobinopathy Care
-
Jun 29, 2026, 20:05Anisha Navkudkar: TMH Blood Centre Received the Ravi Reddy Award 2026 at ISBT Congress
-
Jun 29, 2026, 20:03Anirban Sen Gupta: Congratulations Christopher Delianides for a Fantastic Dissertation and Graduate Research Presentation
-
Jun 29, 2026, 20:01May Guo: Inhibiting Anti-PEG Antibody Binding With Randomized PEG
-
Jun 29, 2026, 15:50Sweta Agrawal: Expanding Care for PNH Patients in Nepal
-
Jun 29, 2026, 15:17Heghine Khachatryan: Hemostasis at the Crossroads of Thrombosis and Bleeding
-
Jun 29, 2026, 15:07Tomaz Crochemore: From Bleeding to Thrombosis – The Era of Precision Hemostatic Medicine Has Arrived
-
Jun 29, 2026, 14:51Pete Stibbs: Building a Successful Venous Thrombectomy Practice